Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

377 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry.
Mountzios G, Planchard D, Metro G, Tsiouda D, Prelaj A, Lampaki S, Shalata W, Riudavets M, Christopoulos P, Girard N, Albarrán-Artahona V, Garcia Campelo R, Samitas K, Banna GL, Boukovinas I, Agbarya A, Koumarianou A, Perdikouri EI, Kosmidis P, Linardou H, Mauri D, Mavroudis D, Athanasiadis I, Kalofonos H, Xenidis N, Korantzis I, Ardavanis A, Rallis G, Bottiglieri A, Efthymiadis K, Oikonomopoulos G, Kokkalis A, Saloustros E, Tsoukalas N, Bartzi D, Economopoulou P, Psyrri A, Reck M, Lo Russo G. Mountzios G, et al. Among authors: kalofonos h. JTO Clin Res Rep. 2022 Nov 20;4(1):100433. doi: 10.1016/j.jtocrr.2022.100433. eCollection 2023 Jan. JTO Clin Res Rep. 2022. PMID: 36793384 Free PMC article.
Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia.
Mountzios G, Aravantinos G, Alexopoulou Z, Timotheadou E, Matsiakou F, Christodoulou C, Laschos K, Galani E, Koutras A, Bafaloukos D, Linardou H, Pectasides D, Varthalitis I, Papakostas P, Kalofonos HP, Fountzilas G. Mountzios G, et al. Among authors: kalofonos hp. Mol Clin Oncol. 2016 Feb;4(2):211-220. doi: 10.3892/mco.2015.693. Epub 2015 Dec 4. Mol Clin Oncol. 2016. PMID: 26893865 Free PMC article.
Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
Papadimitriou CA, Bafaloukos D, Bozas G, Kalofonos H, Kosmidis P, Aravantinos G, Fountzilas G, Dimopoulos MA; Hellenic Co-operative Oncology Group. Papadimitriou CA, et al. Among authors: kalofonos h. Gynecol Oncol. 2008 Jul;110(1):87-92. doi: 10.1016/j.ygyno.2008.03.004. Epub 2008 May 2. Gynecol Oncol. 2008. PMID: 18455782 Clinical Trial.
Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A, Lazaridis G, Koliou GA, Kouvatseas G, Christodoulou C, Pectasides D, Kotoula V, Batistatou A, Bobos M, Tsolaki E, Papadopoulou K, Pentheroudakis G, Papakostas P, Pervana S, Petraki K, Chrisafi S, Razis E, Psyrri A, Bafaloukos D, Kalogeras KT, Kalofonos HP, Fountzilas G. Koutras A, et al. PLoS One. 2018 Dec 6;13(12):e0207707. doi: 10.1371/journal.pone.0207707. eCollection 2018. PLoS One. 2018. PMID: 30521571 Free PMC article.
The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group.
Bamias A, Moulopoulos LA, Koutras A, Aravantinos G, Fountzilas G, Pectasides D, Kastritis E, Gika D, Skarlos D, Linardou H, Kalofonos HP, Dimopoulos MA. Bamias A, et al. Among authors: kalofonos hp. Cancer. 2006 Jan 15;106(2):297-303. doi: 10.1002/cncr.21604. Cancer. 2006. PMID: 16342065 Free article. Clinical Trial.
Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab.
Christodoulou C, Oikonomopoulos G, Koliou GA, Kostopoulos I, Kotoula V, Bobos M, Pentheroudakis G, Lazaridis G, Skondra M, Chrisafi S, Koutras A, Bafaloukos D, Razis E, Papadopoulou K, Papakostas P, Kalofonos HP, Pectasides D, Skarlos P, Kalogeras KT, Fountzilas G. Christodoulou C, et al. Cancer Genomics Proteomics. 2018 Nov-Dec;15(6):461-471. doi: 10.21873/cgp.20105. Cancer Genomics Proteomics. 2018. PMID: 30343280 Free PMC article.
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G, Pectasides D, Kalogera-Fountzila A, Skarlos D, Kalofonos HP, Papadimitriou C, Bafaloukos D, Lambropoulos S, Papadopoulos S, Kourea H, Markopoulos C, Linardou H, Mavroudis D, Briasoulis E, Pavlidis N, Razis E, Kosmidis P, Gogas H. Fountzilas G, et al. Among authors: kalofonos hp. Breast Cancer Res Treat. 2005 Jul;92(1):1-9. doi: 10.1007/s10549-005-0322-y. Breast Cancer Res Treat. 2005. PMID: 15980985 Clinical Trial.
Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
Pentheroudakis G, Briasoulis E, Kalofonos HP, Fountzilas G, Economopoulos T, Samelis G, Koutras A, Karina M, Xiros N, Samantas E, Bamias A, Pavlidis N; Hellenic Cooperative Oncology Group. Pentheroudakis G, et al. Acta Oncol. 2008;47(6):1148-55. doi: 10.1080/02841860701843043. Acta Oncol. 2008. PMID: 18607872 Clinical Trial.
Irinotecan and oxaliplatin combination, as second-line treatment, in fluoropyrimidine-pretreated advanced colorectal cancer. A phase II study by the Hellenic Cooperative Oncology Group (HeCOG).
Timotheadou E, Papakostas P, Tsavdaridis D, Basdanis G, Kalofonos H, Aravantinos G, Bafaloukos D, Fountzilas G. Timotheadou E, et al. Among authors: kalofonos h. Tumori. 2005 Jul-Aug;91(4):309-13. doi: 10.1177/030089160509100404. Tumori. 2005. PMID: 16277094 Clinical Trial.
The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival.
Tsamandas AC, Kardamakis D, Ravazoula P, Zolota V, Salakou S, Tepetes K, Kalogeropoulou C, Tsota I, Kourelis T, Makatsoris T, Karavias D, Scopa CD, Bonikos DS, Kalofonos HP, Petsas T. Tsamandas AC, et al. Strahlenther Onkol. 2004 Apr;180(4):201-8. doi: 10.1007/s00066-004-1149-x. Strahlenther Onkol. 2004. PMID: 15057430
377 results